Rothschild Investment LLC Sells 85 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rothschild Investment LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 455 shares of the biopharmaceutical company’s stock after selling 85 shares during the quarter. Rothschild Investment LLC’s holdings in Regeneron Pharmaceuticals were worth $324,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Private Wealth Management Group LLC lifted its position in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the subject of several research reports. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, TD Cowen dropped their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $723.47 on Wednesday. The company has a market cap of $79.09 billion, a price-to-earnings ratio of 18.90, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $698.84 and a 200-day moving average of $875.48.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.